Stay updated on Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The website has been updated to version v2.10.0, adding 3 more interventions/treatments, 4 more study numbers, and noting that the study now has 158 locations.
    Difference
    0.3%
    Check dated 2024-07-23T15:38:22.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T08:43:13.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the web page content.
    Difference
    0.0%
    Check dated 2024-07-02T15:42:43.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Last Update Posted (Estimated) Revision has changed from v2.9.3 to v2.9.5, indicating an update in the study record details.
    Difference
    0.0%
    Check dated 2024-06-27T12:02:22.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value 2023-10-06 2024-06-21 2023-10-04 Last Update Posted 2023-10-06 2023-09 Revision: v2.9.1 has recently changed to 2024-06-25 2024-08-30 2024-06-24 Last Update Posted (Estimated) 2024-06-25 2024-06 Revision: v2.9.3. The update represents a change in the study record dates, including the last update posted and the revision version, indicating recent modifications and updates to the study information.
    Difference
    0.5%
    Check dated 2024-06-26T10:39:28.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus Genetics related topics: Lung cancer MedlinePlus related topics: Lung Cancer Drug Information available for: Pemetrexed Pemetrexed disodium Lenvatinib Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Double ( Participant Investigator ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years. Biological : Pembrolizumab IV infusion Q3W Other Names: MK-3475 Drug : Carboplatin IV infusion Q3W Drug : Cisplatin IV infusion Q3W Drug : Pemetrexed IV infusion Q3W Drug : Lenvatinib Oral capsule once daily Other Names: MK-7902 E7080 Placebo Comparator : Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
    Difference
    35%
    Check dated 2024-06-25T09:39:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page.